201 related articles for article (PubMed ID: 30993548)
21. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
Ito T; Suzuki K; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
[TBL] [Abstract][Full Text] [Related]
22. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
[TBL] [Abstract][Full Text] [Related]
23. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the structure, function and autophagic maintenance of mitochondria in nigrostriatal and tuberoinfundibular dopamine neurons.
Hawong HY; Patterson JR; Winner BM; Goudreau JL; Lookingland KJ
Brain Res; 2015 Oct; 1622():240-51. PubMed ID: 26141374
[TBL] [Abstract][Full Text] [Related]
25. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
27. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
28. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
[TBL] [Abstract][Full Text] [Related]
29. ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp1-mediated aberrant mitochondrial fission in Parkinson's disease.
Zhang Q; Hu C; Huang J; Liu W; Lai W; Leng F; Tang Q; Liu Y; Wang Q; Zhou M; Sheng F; Li G; Zhang R
Exp Mol Med; 2019 Oct; 51(10):1-13. PubMed ID: 31578315
[TBL] [Abstract][Full Text] [Related]
30. Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1.
Geng J; Liu W; Gao J; Jiang C; Fan T; Sun Y; Qin ZH; Xu Q; Guo W; Gao J
Br J Pharmacol; 2019 Dec; 176(23):4574-4591. PubMed ID: 31389613
[TBL] [Abstract][Full Text] [Related]
31. Participation of perforin in mediating dopaminergic neuron loss in MPTP-induced Parkinson's disease in mice.
Peng SP; Zhang Y; Copray S; Schachner M; Shen YQ
Biochem Biophys Res Commun; 2017 Mar; 484(3):618-622. PubMed ID: 28137589
[TBL] [Abstract][Full Text] [Related]
32. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
Ding H; Underwood R; Lavalley N; Yacoubian TA
Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634
[TBL] [Abstract][Full Text] [Related]
33. Upregulated hexokinase 2 expression induces the apoptosis of dopaminergic neurons by promoting lactate production in Parkinson's disease.
Li J; Chen L; Qin Q; Wang D; Zhao J; Gao H; Yuan X; Zhang J; Zou Y; Mao Z; Xiong Y; Min Z; Yan M; Wang CY; Xue Z
Neurobiol Dis; 2022 Feb; 163():105605. PubMed ID: 34973450
[TBL] [Abstract][Full Text] [Related]
34. Mfn2 Overexpression Attenuates MPTP Neurotoxicity In Vivo.
Zhao F; Austria Q; Wang W; Zhu X
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435331
[TBL] [Abstract][Full Text] [Related]
35. Ablation of RIP3 protects from dopaminergic neurodegeneration in experimental Parkinson's disease.
Dionísio PA; Oliveira SR; Gaspar MM; Gama MJ; Castro-Caldas M; Amaral JD; Rodrigues CMP
Cell Death Dis; 2019 Nov; 10(11):840. PubMed ID: 31690718
[TBL] [Abstract][Full Text] [Related]
36. Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons.
Masi A; Narducci R; Resta F; Carbone C; Kobayashi K; Mannaioni G
Eur J Neurosci; 2015 Nov; 42(9):2699-706. PubMed ID: 26354486
[TBL] [Abstract][Full Text] [Related]
37. Differences in Neuronal Numbers, Morphology, and Developmental Apoptosis in Mice Nigra Provide Experimental Evidence of Ontogenic Origin of Vulnerability to Parkinson's Disease.
Vidyadhara DJ; Yarreiphang H; Raju TR; Alladi PA
Neurotox Res; 2021 Dec; 39(6):1892-1907. PubMed ID: 34762290
[TBL] [Abstract][Full Text] [Related]
38. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
[TBL] [Abstract][Full Text] [Related]
39. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
40. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
